ReviewGastroenterology2019
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.
Review in Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed.
- [A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Trial
- Epigenetic scars of CD8Nature immunology · 2021Trial
- Article
- Modeling Highlights the Challenge of Achieving and Maintaining Hepatitis C Virus Micro-Elimination Among People Who Inject Drugs.Open forum infectious diseases · 2026Article
- The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.Journal of virology · 2026Article
- Pampa biome plant extracts and flavonoids show antiviral activity against Bovine Herpesvirus and Bovine Viral Diarrhea Virus.Scientific reports · 2026Article
- Fibrotic, metabolic and clinical improvements in patients with chronic hepatitis C treated with direct-acting antiviral therapy in a resource limited setting: a prospective cohort study.BMC gastroenterology · 2026Article
- China data on the burden of alcohol-associated liver cancer from 1990 to 2021: a systematic analysis from the global burden of disease study 2021.Ecancermedicalscience · 2026Article
- Hepatitis B and Delta and the role of the Fundação de Medicina Tropical Dr. Heitor Vieira Dourado.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
- Hepatitis C missed diagnostic opportunities: The role of reflex viral load testing in the era of direct acting antivirals, a descriptive South African study from 2017 to 2021.Southern African journal of infectious diseases · 2026Article
- Multiple Approaches to Genetic Sequencing to Identify Hepatitis C Virus Reinfection Among People Who Inject Drugs.The Journal of infectious diseases · 2025Article
- Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study.Clinical and molecular hepatology · 2025Article
- Evaluation of hyaluronic acid and type III procollagen peptide as predictors for treatment response to direct-acting antivirals.World journal of virology · 2025Article
- Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.BMJ open gastroenterology · 2025Article
- Article
- Impact of HIV co-infection on liver fibrosis regression after HCV treatment.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Tubulointerstitial nephritis antigen-like 1 promotes the progression of liver fibrosis after HCV eradication with direct-acting antivirals.International journal of biological sciences · 2025Article
- Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy.Pathogens (Basel, Switzerland) · 2024Review
- Roseoside Is a Bioactive Compound inMolecules (Basel, Switzerland) · 2024Article
- Acacetin, a Natural Flavone with Potential in Improving Liver Disease Based on Its Anti-Inflammation, Anti-Cancer, Anti-Infection and Other Effects.Molecules (Basel, Switzerland) · 2024Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chronic infection with hepatitis C virus is a major cause of liver disease and hepatocellular carcinoma worldwide. After the discovery of hepatitis C virus 3 decades ago, the identification of the structure of the viral proteins, combined with high-throughput replicon models, enabled the discovery and development of direct-acting antivirals. These agents have revolutionized patient care, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies for hepatitis C virus infection and discuss remaining challenges. We highlight licensed compounds, discuss the potential to shorten therapy even further, and review different options for treatment failure and resistance. We also provide an overview of clinical experience with generic agents and evidence for their efficacy. Finally, we discuss the need for new drugs and outline promising targets for future therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.